Heat shock protein inhibitors - Pipeline Insight, 2024

Heat shock protein inhibitors - Pipeline Insight, 2024

DelveInsight’s, “Heat Shock Protein (Hsp) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Heat Shock Protein (Hsp) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Heat Shock Protein (Hsp) Inhibitor Understanding

Heat Shock Protein (Hsp) Inhibitor: Overview

Heat Shock Proteins (HSPs) are a family of proteins that are transcriptionally upregulated under cellular stress including exposure to heat/ UV/ cold/pH changes, tissue remodeling etc. The HSPs are also called as ""chaperone"" proteins as they bind and assist in correct protein folding and also help in refolding improperly folded proteins.

Function - Heat shock protein 90 (HSP90) is an important member of the chaperone protein family and it is involved in stabilization, regulation, and maintenance of oncogenic client proteins with co-chaperones. Cochaperones regulate the ATPase activity of HSP90 and its interactions with oncogenic client proteins. Therefore, HSP90 and its co-chaperones have become important therapeutic targets for cancer treatment. This has led to the development of several inhibitors of HSP90 and other HSPs that have shown promise both preclinically and clinically in the treatment of cancer.

Heat Shock Protein (Hsp) Inhibitor - An Hsp90 inhibitor is a substance that inhibits that activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. Furthermore, a number of Hsp90 inhibitors are currently undergoing clinical trials for a variety of cancers. Hsp90 inhibitors include the natural products geldanamycin and radicicol as well as semisynthetic derivatives.

Heat Shock Protein (Hsp) Inhibitor Emerging Drugs Chapters

This segment of the Heat Shock Protein (Hsp) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Heat Shock Protein (Hsp) Inhibitor Emerging Drugs

• Pimitespib (TAS 116): Taiho Pharmaceutical

TAS-116, a compound discovered by Taiho Pharmaceutical, inhibits HSP90, thereby showing an anticancer effect by destabilizing and reducing proteins such as KIT, PDGFRA, HER2, and EGFR which are involved in the growth and survival of cancer. It is currently in phase 3 stage of clinical trials for the treatment of Gastrointestinal stromal tumours

• RTA 901: Reata Pharmaceuticals

RTA 901 is a highly potent and selective, oral, small molecule C-terminal modulator of Hsp90. In preclinical rodent disease models, it was observed that RTA 901 administered orally once-daily rescued existing nerve function, restored thermal and mechanical sensitivity within four weeks, and improved nerve conductance velocity and mitochondrial function. These effects are dose-dependent, reversible, and HSP70-dependent.currently, it is in phase 1 of development stage for the treatment of Diabetic neuropathies.

Further product details are provided in the report……..

Heat Shock Protein (Hsp) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Heat Shock Protein (Hsp) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Heat Shock Protein (Hsp) Inhibitor

There are approx. 15+ key companies which are developing the Heat Shock Protein (Hsp) Inhibitor. The companies which have their Heat Shock Protein (Hsp) Inhibitor drug candidates in the most advanced stage, i.e. phase III include, Taiho Pharmaceutical.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Heat Shock Protein (Hsp) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Heat Shock Protein (Hsp) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heat Shock Protein (Hsp) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heat Shock Protein (Hsp) Inhibitor drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Heat Shock Protein (Hsp) Inhibitor R&D. The therapies under development are focused on novel approaches for Heat Shock Protein (Hsp) Inhibitor.

Heat Shock Protein (Hsp) Inhibitor Report Insights

• Heat Shock Protein (Hsp) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Heat Shock Protein (Hsp) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Heat Shock Protein (Hsp) Inhibitor drugs?
• How many Heat Shock Protein (Hsp) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Heat Shock Protein (Hsp) Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heat Shock Protein (Hsp) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Heat Shock Protein (Hsp) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Taiho Pharmaceutical
• Reata Pharmaceuticals
• Soligenix
• Exelixis
• Third Coast Therapeutics
• Serenex
• Chia Tai Tianqing Pharmaceutical Group
• Wakamoto
• Samus Therapeutics
• Aldeyra Therapeutics
• Joseah Biopharma
• Novartis
• Vernalis
• Astex Pharmaceuticals
• Minneamrita Therapeutics
• RESprotect

Key Products

• Pimitespib (TAS 116)
• RTA 901
• XL 888
• 3 crx 98
• SNX 5422
• TQB 3474
• WP 1303
• Zelavespib
• ADX-1612
• ADX-1615
• MPT0B640
• NVP BEP 800
• Onalespib
• Minnelide
• Brivudine